Genting Shine (01952.HK) announced that the new drug "VELSIPITY", used to treat moderate to severe active ulcerative colitis in adult patients, has officially been accepted by the Hong Kong Department of Health for market authorization application. The product was approved for marketing by the Macau Health Bureau in April this year and was launched in the Greater Bay Area in October through the "Hong Kong-Macao Medical Device Platform."

Genting Shine's CEO, Luo Yongqing, plans to submit the new drug application for VELSIPITY in mainland china this year, expecting it to be approved in more regions to further expand accessibility and benefit patients.